Abanoquil mesylate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526525

CAS#: 118931-00-3 (mesylate)

Description: Abanoquil, also known as UK 52046, is an alpha-1 adrenoceptor antagonist. Abanoquil is able to relax contracted tissue strips and induce erectile response when injected intracorporally. The erectile response in the monkeys was not dose-related and compared to the effect of papaverine injections, abanoquil induced a lower level of tumescence and rigidity. Hence, abanoquil might be useful as a facilitator of erection in the pharmacological treatment of erectile dysfunction.


Chemical Structure

img
Abanoquil mesylate
CAS# 118931-00-3 (mesylate)

Theoretical Analysis

MedKoo Cat#: 526525
Name: Abanoquil mesylate
CAS#: 118931-00-3 (mesylate)
Chemical Formula: C23H29N3O7S
Exact Mass: 0.00
Molecular Weight: 491.560
Elemental Analysis: C, 56.20; H, 5.95; N, 8.55; O, 22.78; S, 6.52

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 118931-00-3 (mesylate)   90402-40-7 (free base)    

Synonym: UK 52046; UK-52046; UK52046; Abanoquil; Abanoquil mesylate;

IUPAC/Chemical Name: 4-Quinolinamine, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy-, methanesulfonate (1:1)

InChi Key: FMDPOTBKJNHQLC-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H25N3O4.CH4O3S/c1-26-18-7-13-5-6-25(12-14(13)8-19(18)27-2)22-10-16(23)15-9-20(28-3)21(29-4)11-17(15)24-22;1-5(2,3)4/h7-11H,5-6,12H2,1-4H3,(H2,23,24);1H3,(H,2,3,4)

SMILES Code: NC1=CC(N2CC3=C(C=C(OC)C(OC)=C3)CC2)=NC4=CC(OC)=C(OC)C=C14.CS(=O)(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 491.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Giraldi A, Wyllie M, Wagner G. Abanoquil, a new alpha-1 adrenoceptor antagonist. In vitro and in vivo effect on erectile tissue. Int J Impot Res. 2000 Mar;12 Suppl 1:S37-40. PMID: 10845763.


2: Giraldi A, Wyllie M, Wagner G. Abanoquil, a new alpha-1 adrenoceptor antagonist. In vitro and in vivo effect on erectile tissue. Int J Impot Res. 2000 Mar;12(S1):S37-S40. PMID: 10849564.


3: Ho SL, Honner V, Docherty JR. Investigation of the subtypes of alpha2-adrenoceptor mediating prejunctional inhibition in rat atrium and cerebral cortex. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jun;357(6):634-9. doi: 10.1007/pl00005218. PMID: 9686939.


4: Anyukhovsky EP, Guo SD, Danilo P Jr, Rosen MR. Responses to norepinephrine of normal and "ischemic" canine Purkinje fibers are consistent with activation of different alpha 1-receptor subtypes. J Cardiovasc Electrophysiol. 1997 Jun;8(6):658-66. doi: 10.1111/j.1540-8167.1997.tb01829.x. PMID: 9209967.


5: Yasutake M, Avkiran M. Effects of selective alpha 1A-adrenoceptor antagonists on reperfusion arrhythmias in isolated rat hearts. Mol Cell Biochem. 1995 Jun 7-21;147(1-2):173-80. doi: 10.1007/BF00944798. PMID: 7494547.


6: Chess-Williams R, Aston N, Couldwell C. Alpha 1A-adrenoceptor subtype mediates contraction of the rat urethra. J Auton Pharmacol. 1994 Dec;14(6):375-81. doi: 10.1111/j.1474-8673.1994.tb00618.x. PMID: 7876271.


7: Chapple CR, Burt RP, Andersson PO, Greengrass P, Wyllie M, Marshall I. Alpha 1-adrenoceptor subtypes in the human prostate. Br J Urol. 1994 Nov;74(5):585-9. doi: 10.1111/j.1464-410x.1994.tb09188.x. PMID: 7530122.


8: Toivonen L. Influence of acute alpha 1-adrenergic antagonism on heart rate variability in patients with old myocardial infarction. J Cardiovasc Pharmacol. 1994 Jun;23(6):932-5. doi: 10.1097/00005344-199406000-00011. PMID: 7523785.


9: Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8. PMID: 8183249.


10: Vanoli E, Hull SS Jr, Foreman RD, Ferrari A, Schwartz PJ. Alpha 1-adrenergic blockade and sudden cardiac death. J Cardiovasc Electrophysiol. 1994 Jan;5(1):76-89. doi: 10.1111/j.1540-8167.1994.tb01116.x. PMID: 7910510.


11: Kaye B, Clark MW, Cussans NJ, Macrae PV, Stopher DA. The sensitive determination of abanoquil in blood by high-performance liquid chromatography/atmospheric pressure ionization mass spectrometry. Biol Mass Spectrom. 1992 Nov;21(11):585-9. doi: 10.1002/bms.1200211110. PMID: 1360817.


12: Tham TC, Guy S, Shanks RG, Harron DW. Dose-dependent alpha 1-adrenoceptor antagonist activity of the anti-arrhythmic drug, abanoquil (UK-52,046), without reduction in blood pressure in man. Br J Clin Pharmacol. 1992 Apr;33(4):405-9. doi: 10.1111/j.1365-2125.1992.tb04059.x. PMID: 1349492; PMCID: PMC1381330.


13: Schafers RF, Elliott HL, Meredith PA, Miller SH, Reid JL. Studies with abanoquil (UK-52,046) a novel quinoline alpha 1-adrenoceptor antagonist: II. Duration of action, pharmacokinetics and concentration-effect relationships in normotensive subjects. Br J Clin Pharmacol. 1991 Nov;32(5):605-10. doi: 10.1111/j.1365-2125.1991.tb03959.x. PMID: 1683250; PMCID: PMC1368638.


14: Schafers RF, Elliott HL, Howie CA, Reid JL. Studies with abanoquil (UK-52,046) a novel quinoline alpha 1-adrenoceptor antagonist: I. Effects on blood pressure, heart rate and pressor responsiveness in normotensive subjects. Br J Clin Pharmacol. 1991 Nov;32(5):599-604. doi: 10.1111/j.1365-2125.1991.tb03958.x. PMID: 1683249; PMCID: PMC1368637.


15: Flores NA, Sheridan DJ. Electrophysiological effects of alpha-adrenoceptor stimulation in perfused and superfused myocardium. J Mol Cell Cardiol. 1991 Aug;23(8):973-85. doi: 10.1016/0022-2828(91)90139-d. PMID: 1682501.


16: Spiers JP, Harron DW, Wilson R. Duration of action and effect on baroreflex function of the anti-arrhythmic alpha 1 antagonist UK-52,046. J Pharm Pharmacol. 1991 Jan;43(1):70-2. doi: 10.1111/j.2042-7158.1991.tb05457.x. PMID: 1676070.


17: Spiers JP, Harron DW, Wilson R, Allen JD. UK-52,046 (a novel alpha 1-adrenoceptor antagonist) and the role of alpha-adrenoceptor stimulation and blockade on atrioventricular conduction. J Cardiovasc Pharmacol. 1990 Nov;16(5):824-30. doi: 10.1097/00005344-199011000-00020. PMID: 1703607.


18: McKaigue JP, Harron DW. Effect of UK-52,046, an alpha 1-adrenoceptor antagonist, on baroreflex function in man. Br J Clin Pharmacol. 1990 Oct;30(4):579-84. doi: 10.1111/j.1365-2125.1990.tb03816.x. PMID: 1981319; PMCID: PMC1368248.


19: Silke B, Zezulka AV, Verma SP, Tham TC, Taylor SH. Haemodynamic dose- response effects of UK-52,046 in ischaemic disease with or without impaired left ventricular function. Br J Clin Pharmacol. 1990 Jun;29(6):749-58. doi: 10.1111/j.1365-2125.1990.tb03697.x. PMID: 1974144; PMCID: PMC1380178.


20: Barin ES, Wong CK, Elstob JE, Davies DW, Nathan AW. An acute study of the electrophysiological and haemodynamic effects of intravenous UK-52,046, a novel alpha 1-adrenoceptor antagonist. Br J Clin Pharmacol. 1990 Mar;29(3):359-62. doi: 10.1111/j.1365-2125.1990.tb03648.x. PMID: 1968756; PMCID: PMC1380138.